Email Us
Call Us
AUSTIN, Texas – June 10, 2026 – Preclinical research performed at Altogen Labs for Turn Therapeutics Inc. (Nasdaq: TTRX) has been published in the peer-reviewed Journal of Dermatological Treatment, reporting the activity of the company’s lead candidate GX-03 in an IL-36–associated inflammatory environment.
The publication, “Effects of extended-release topical polyhexanide in a Staphylococcus aureus-induced murine dermatitis model characterized by IL-36 expression,” describes a model in which IL-36 protein expression was confirmed following S. aureus exposure, establishing the inflammatory environment against which the compound was evaluated. Mice treated twice daily with GX-03 for seven days achieved a mean investigator global assessment score of 1.44 compared with 3.00 in untreated controls (p = 0.0003). No treatment-related adverse effects were observed.
Peer review is an independent audit of experimental design and execution. When work performed at Altogen Labs clears that bar in an established clinical journal, it confirms what sponsors rely on: study conduct that will withstand scrutiny from reviewers, regulators, and investors alike. The work also illustrates the breadth of the Altogen Labs infectious disease and inflammation capability – bacterial challenge models, standardized clinical scoring, cytokine quantification, and histopathology – running in parallel with the company’s oncology programs.
Altogen Labs conducts preclinical research across oncology, inflammation, immunology, dermatology, infectious disease, neurodegenerative disease, pain, and metabolic disorders from its GLP-compliant, IACUC-regulated facility in Austin, Texas.
About Altogen Labs Altogen Labs is a professional, experienced, and highly reputable GLP-compliant contract research organization providing preclinical research and biology CRO services worldwide, offering a large collection of in-house validated xenograft models and extensive experience in efficacy xenograft studies and safety toxicology studies.
Contact Information: Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com
Source citation: Turn Therapeutics Inc. (Nasdaq: TTRX), “Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model,” Business Wire, May 27, 2026.